Skip to main content
SpringerLink
Log in

Renal Cancer Pathogenesis

  • Living reference work entry
  • First Online:
Encyclopedia of Cancer

  • 28 Accesses

Characteristics

Conventional or Clear-Cell Renal Cell Carcinoma (ccRCC). Clear-cell renal cell carcinoma (ccRCC) accounts for approximately 75 % of all renal epithelial cancers, is the most frequent malignant neoplasm arising from the kidney, and is the most common cause of death in patients with von Hippel-Lindau disease (VHL; von Hippel-Lindau tumor suppressor gene), an autosomal dominant familial cancer syndrome. This syndrome is comprised of retinal angiomas, hemangioblastomas of the central nervous system, pheochromocytoma, endolymphatic sac tumors of the middle ear, serous cystadenomas and neuroendocrine tumors of the pancreas, papillary cystadenomas of the epididymis or broad ligament, and ccRCC. In von Hippel-Lindau disease, one VHL mutant allele is inherited. In a majority of cases, ccRCC arises from acquired mutation or silencing of the remaining wild-type allele. The use of tobacco (tobacco carcinogenesis) appears to be a major risk factor in patients with sporadic disease.

T...

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Costa LJ, Drabkin HA (2007) Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. Oncologist 12(12):1404–1415

    Article  CAS  PubMed  Google Scholar 

  • Escudier B, Eisen T, Stadler WM et al (2007a) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125–134

    Article  CAS  PubMed  Google Scholar 

  • Escudier B, Koralewski P, Pluzanska A et al (2007b) A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon alpha-2a vs. placebo/interferon alpha-2a as first-line therapy in metastatic renal cell carcinoma. J Clin Oncol 25(S):3

    Google Scholar 

  • Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271–2281

    Article  CAS  PubMed  Google Scholar 

  • Hutson TE, Figlin RA (2007) Renal cell cancer. Cancer J 13(5):282–286

    Article  CAS  PubMed  Google Scholar 

  • Linehan WM, Vasselli J, Srinivasan R et al (2004) Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res 10(18 Pt 2):6282S–6289S

    Article  CAS  PubMed  Google Scholar 

  • McDermott DF, Regan MM, Clark JI et al (2005) Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23(1):133–141

    Article  CAS  PubMed  Google Scholar 

  • Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124

    Article  CAS  PubMed  Google Scholar 

  • Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449–456

    Article  CAS  PubMed  Google Scholar 

  • Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349(5):427–434

    Article  CAS  PubMed  PubMed Central  Google Scholar 

See Also

  • (2012) Autosomal Dominant. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 323. doi:10.1007/978-3-642-16483-5_489

    Google Scholar 

  • (2012) Cell Cycle. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 737. doi:10.1007/978-3-642-16483-5_994

    Google Scholar 

  • (2012) Interleukin-2. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1892. doi:10.1007/978-3-642-16483-5_3097

    Google Scholar 

  • (2012) KIT. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, pp 1945–1946. doi:10.1007/978-3-642-16483-5_3228

    Google Scholar 

  • (2012) MTOR. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2384. doi:10.1007/978-3-642-16483-5_3867

    Google Scholar 

  • (2012) Normoxia. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2557. doi:10.1007/978-3-642-16483-5_4129

    Google Scholar 

  • (2012) Paraneoplastic Syndromes. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, pp 2784-2785. doi:10.1007/978-3-642-16483-5_4387

    Google Scholar 

  • (2012) Penetrance. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2806. doi:10.1007/978-3-642-16483-5_4437

    Google Scholar 

  • (2012) Prodrug. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2989. doi:10.1007/978-3-642-16483-5_4751

    Google Scholar 

  • (2012) Reciprocal Translocation. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 3204. doi:10.1007/978-3-642-16483-5_4989

    Google Scholar 

  • (2012) Sunitinib. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 3562. doi:10.1007/978-3-642-16483-5_5575

    Google Scholar 

  • (2012) Transforming Growth Factor Alpha. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 3758. doi:10.1007/978-3-642-16483-5_5915

    Google Scholar 

  • (2012) Translation Initiation Complex. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 3770. doi:10.1007/978-3-642-16483-5_5937

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology-Oncology, Medical University of South Carolina and the Hollings Cancer Center, Charleston, SC, USA

    Harry A. Drabkin

  2. Compassionate Oncology Medical Group, Los Angeles, CA, USA

    Jeffrey Turner

Authors
  1. Harry A. Drabkin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffrey Turner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Harry A. Drabkin .

Editor information

Editors and Affiliations

  1. Abt. Tumorgenetik, Deutsches Krebsforschungszentrum, Heidelberg, Germany

    Manfred Schwab

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this entry

Cite this entry

Drabkin, H.A., Turner, J. (2014). Renal Cancer Pathogenesis. In: Schwab, M. (eds) Encyclopedia of Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-27841-9_6324-2

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-27841-9_6324-2

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Online ISBN: 978-3-642-27841-9

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics

Search

Navigation